Telephone: +34-948-296637; FAX: +34-948-296500
De novo malignancies following liver transplantation: Impact and recommendations
Article first published online: 29 OCT 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Supplement: ILTS/AASLD Transplant Course: Long-Term Outcomes of Adult and Pediatric Liver Transplantation
Volume 15, Issue Supplement S2, pages S90–S94, November 2009
How to Cite
Herrero, J. I. (2009), De novo malignancies following liver transplantation: Impact and recommendations. Liver Transpl, 15: S90–S94. doi: 10.1002/lt.21898
- Issue published online: 29 OCT 2009
- Article first published online: 29 OCT 2009
- Manuscript Accepted: 20 AUG 2009
- Manuscript Received: 30 APR 2009
- Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas is funded by the Instituto de Salud Carlos III
1. De novo malignancy is one of the leading causes of late mortality after liver transplantation.
2. The risks of skin cancers and lymphoma are more than 10-fold greater than the risks in an age-matched and sex-matched general population.
3. Some types of neoplasia, such as lung, head and neck, and colorectal cancer, are more frequent in liver transplant recipients than in an age-matched and sex-matched population. The risks of other frequent malignancies, such as prostate and breast cancer, do not seem to be increased.
4. The most important risks for posttransplant malignancy are Epstein-Barr virus seronegativity (for lymphoma), sun exposure (for skin cancer), smoking, and increasing age.
5. Despite the absence of evidence, general recommendations (such as avoidance of overimmunosuppression, sunlight protection, and cessation of smoking) should be given. Screening protocols may help to detect neoplasia at an early stage of disease. Liver Transpl 15:S90–S94, 2009. © 2009 AASLD.